NanoString Introduces Rat miRNA Expression Assays

Kit Enables Profiling of More than 400 Rat miRNAs in a Single Tube without Amplification

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter® Rat miRNA Expression Assay Kit for use on its nCounter Analysis System.

The nCounter Rat miRNA Expression Assay Kit enables researchers to perform direct digital detection and counting of tissue-specific miRNAs at single-base resolution, without the need for amplification. The kit provides the capacity to perform multiplexed profiling of more than 400 rat miRNAs in a single tube, with specificity and sensitivity comparable to qPCR. Like all nCounter assays, the kit is compatible with multiple sample types, including FFPE samples.

“Our customers investigating the role of miRNAs in toxicogenomics, mutagenesis and neuroscience have asked us to expand our portfolio of miRNA products to enable their research in rat,” said Barney Saunders, Chief Commercial Officer for NanoString Technologies. “We are pleased to offer these researchers a product that, true to our entire line of nCounter assays, is both sensitive and simple to use.”

The nCounter Analysis System is a fully automated digital detection and counting system with a very simple workflow. The assay kits contain all of the reagents and consumables required to conduct an experiment. Minimal sample input requirements and compatibility with a variety of sample types, extends the utility of the platform. In addition to miRNA assays, NanoString provides assays for copy number variation and gene expression analysis. The nCounter Analysis System is currently available for Research Use Only.

More information is available at www.NanoString.com.

About NanoString Technologies, Inc.

NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.

The nCounter platform is for Research Use Only. Not for use in diagnostic procedures.



CONTACT:

For NanoString Technologies, Inc.
Nicole Litchfield, 415-793-6468
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Medical Devices  Oncology  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.